Telescope Announces Results of its Annual General Meeting
April 29, 2022 — Shareholders elected Prof. Jason Hein, Robert Mintak, James Andrew Robinson, Ali Pejman, and Henry Dubina as directors of the Company.
Telescope expects proposal for a new board member at upcoming AGM
April 26, 2022 — Henry Dubina, the ex-president and strategic business unit head of Mettler-Toledo Autochem, is expected to be nominated as an independent director of Telescope.
Telescope Launches Strategic Division for Industrial Chemical Manufacturing and Announces First Client
April 25, 2022 — “Telescope Industries” is a division of the Company dedicated to resolving process and manufacturing inefficiencies in the chemical industry. For its first project, Telescope Industries has been engaged by Hatch Ltd., a global engineering, project management, and professional services firm.
Telescope Announces Testing of Proprietary Compounds for Psychedelic Therapeutic Potential
March 14, 2022 — Positive results from these studies could warrant preclinical development of Telescope’s proprietary compounds as next-generation psychedelic therapeutics.
Telescope Provides a Corporate Update
March 1, 2022 — Over the past year, we have established a growing intellectual property portfolio on pharmaceutical manufacturing,
increased in-house research capacity and proprietary research platforms, and brought in award winning scientific leadership.
Telescope Files Patent Cooperation Treaty Application on Scalable Psilocybin and Tryptamine Synthesis
Jan 17, 2022 — This patent represents a key milestone in addressing the impending manufacturing bottleneck for pharmaceutical-grade psilocybin and psychedelic tryptamines.
Telescope Announces Acquisition of Rights to Synthetic Psilocybin Research
Nov 29, 2021 — We are excited to have come to this agreement with UBC allowing us freedom to own and continue developing our intellectual property.